ATE295899T1 - Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten - Google Patents

Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten

Info

Publication number
ATE295899T1
ATE295899T1 AT99934309T AT99934309T ATE295899T1 AT E295899 T1 ATE295899 T1 AT E295899T1 AT 99934309 T AT99934309 T AT 99934309T AT 99934309 T AT99934309 T AT 99934309T AT E295899 T1 ATE295899 T1 AT E295899T1
Authority
AT
Austria
Prior art keywords
teleosts
activity
screening method
agents activity
screening
Prior art date
Application number
AT99934309T
Other languages
English (en)
Inventor
George N Serbedzija
Carlos Semino
Deanna Frost
Original Assignee
Phylonix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26757274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE295899(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Phylonix Pharmaceuticals Inc filed Critical Phylonix Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE295899T1 publication Critical patent/ATE295899T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/4603—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates from fish
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biodiversity & Conservation Biology (AREA)
AT99934309T 1998-02-23 1999-02-22 Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten ATE295899T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7578398P 1998-02-23 1998-02-23
US10095098P 1998-09-18 1998-09-18
PCT/US1999/003852 WO1999042606A1 (en) 1998-02-23 1999-02-22 Methods of screening agents for activity using teleosts

Publications (1)

Publication Number Publication Date
ATE295899T1 true ATE295899T1 (de) 2005-06-15

Family

ID=26757274

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99934309T ATE295899T1 (de) 1998-02-23 1999-02-22 Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
AT07018743T ATE512233T1 (de) 1998-02-23 1999-02-22 Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07018743T ATE512233T1 (de) 1998-02-23 1999-02-22 Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten

Country Status (8)

Country Link
US (3) US6299858B1 (de)
EP (3) EP1878799B1 (de)
JP (2) JP4383533B2 (de)
AT (2) ATE295899T1 (de)
AU (1) AU749688B2 (de)
CA (1) CA2320406C (de)
DE (1) DE69925362T2 (de)
WO (1) WO1999042606A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US7951989B2 (en) 1998-02-23 2011-05-31 Phylonix Pharmaceuticals, Inc. Methods of screening agents for activity using teleosts
EP1878799B1 (de) * 1998-02-23 2011-06-08 Phylonix Pharmaceuticals, Inc. Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
US6656449B1 (en) 1998-02-23 2003-12-02 Phylonix Pharmaceuticals, Inc. Methods of screening agents for activity using teleosts
CA2353309A1 (en) * 1998-12-09 2000-06-15 Vistagen, Inc. Toxicity typing using embryoid bodies
FR2798392B1 (fr) * 1999-09-13 2005-07-15 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
GR1004180B (el) * 2000-03-28 2003-03-11 ����������� ����� ��������� (����) Μεθοδος και συστημα χαρακτηρισμου και χαρτογραφησης αλλοιωσεων των ιστων
US7250304B2 (en) * 2000-03-31 2007-07-31 The Regents Of The University Of California Functional assay of high-density lipoprotein
US20030040505A1 (en) * 2000-03-31 2003-02-27 The Regents Of The University Of California Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions
EP1290437A1 (de) * 2000-05-27 2003-03-12 Exelixis Deutschland GmbH Verfahren zur identifizierung von agenzien und genen, die die kardiovaskuläre funktion beeinflussen
EP1160570A1 (de) * 2000-05-27 2001-12-05 ARTEMIS Pharmaceuticals GmbH Verfahren zur identifizierung von agenzien und genen, die die kardiovaskuläre Funktion beeinflussen
EP1290444B1 (de) 2000-06-14 2009-10-07 Vistagen, Inc. Toxizitätstypisierung unter verwendung von leberstammzellen
US20020049986A1 (en) * 2000-10-10 2002-04-25 Steven Farber High throughput genetic screening of lipid and cholesterol processing using fluorescent compounds
US6943025B2 (en) 2001-01-10 2005-09-13 Children's Medical Center Corporation Method for identifying genes involved in cell proliferation
JP2003052354A (ja) * 2001-07-18 2003-02-25 Nagoya Industrial Science Research Inst 魚類胚を用いるスクリーニング方法
GB2382579B (en) * 2001-11-30 2003-11-12 Daniolabs Ltd Disease models, assays, methods and means
EP1463820A4 (de) * 2001-12-17 2007-09-05 Childrens Medical Center Verfahren zum screening von verbindungen
ES2295465T3 (es) * 2002-09-16 2008-04-16 Pan-Biotech Gmbh Procedimiento para el cultivo de celulas, en especial de celulas humanas o de animales.
EP1539921B1 (de) * 2002-09-16 2007-11-21 Pan-Biotech GmbH Einrichtung zur kultivierung von zellen, insbesondere menschlicher oder tierischer zellen
US7192770B2 (en) * 2002-09-20 2007-03-20 The General Hospiatal Corporation Screening for skin wrinkling modulators
CA2497560A1 (en) 2002-09-20 2004-04-01 Promega Corporation Luminescence-based methods and probes for measuring cytochrome p450 activity
DE10252806A1 (de) * 2002-11-13 2004-06-03 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Verwendung von Fischlarven als Screening-Modell
WO2004047634A1 (en) * 2002-11-20 2004-06-10 The General Hospital Corporation Zebrafish assay
US7465848B2 (en) * 2002-11-20 2008-12-16 The General Hospital Corporation Zebrafish assay
AU2003303742A1 (en) * 2002-12-24 2004-11-04 Board Of Regents, The University Of Texas System Screening methods using zebrafish to identify thrombotic and anti-thrombotic compounds and genes
GB0301977D0 (en) * 2003-01-28 2003-02-26 Daniolabs Ltd Method for creating a model amenable to high-throughput screening
JP2007507690A (ja) * 2003-09-29 2007-03-29 株式会社 オキシジェニクス 臓器機能の評価方法
GB0403490D0 (en) * 2004-02-17 2004-03-24 Daniolabs Ltd Screening methods
GB2413847A (en) * 2004-04-26 2005-11-09 Daniolabs Ltd Bone disease models
EP1765065B1 (de) * 2004-05-21 2012-06-27 University of Utah Research Foundation Verfahren und zusammensetzungen für die abgabe von chemikalien an embryonen von wirbellosen
US20060063202A1 (en) * 2004-08-11 2006-03-23 John B. Pierce Laboratory High throughput method and system for screening candidate compounds for activity against epilepsy and other neurological diseases
ITRM20050169A1 (it) * 2005-04-07 2006-10-08 Lay Line Genomics Spa Uso di nothobranchius furzeri come sistema modello per la caratterizzazione di geni e farmaci che controllano l'invecchiamento.
EP1885875B1 (de) 2005-05-31 2019-05-22 Promega Corporation Luminogene und fluorogene verbindungen und verfahren für den nachweis von molekülen oder leiden
US7700347B2 (en) * 2005-06-30 2010-04-20 The Forsyth Institute Methods and apparatuses for conducting assays in animals
EP1915607A1 (de) * 2005-07-19 2008-04-30 Physical Sciences, Inc. Microwell-array mit bilderstellung in seitenansicht
FR2889936B1 (fr) 2005-09-01 2007-12-21 Sod Conseils Rech Applic Methode pour quantifier une neurotoxine cholinergique dans un echantillon
GB0523239D0 (en) * 2005-11-14 2005-12-21 Vastox Plc Quantification method
WO2007075753A2 (en) * 2005-12-20 2007-07-05 The Trustees Of The University Of Pennsylvania High through-put method of screening compounds for pharmacological activity
BRPI0710407A2 (pt) * 2006-05-04 2012-04-17 Genentech Inc poliptìdeos, peixes-zebra transgênicos, modelos de sistemas, métodos de identificação de compostos, de identificação de agentes, métodos de tratamento de disfunções relativas a apoptose, método de identificação de agentes de prevenção ou redução da apoptose, composição de aumento da apoptose, composições de redução ou prevenção de apoptose, composição de apoptose, método de detecção, kits e artigo industrializado
WO2008011017A2 (en) * 2006-07-18 2008-01-24 The General Hospital Corporation Methods and compositions for treating vascular disease
US7655832B2 (en) * 2006-08-07 2010-02-02 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Rapid-throughput teleost regeneration assay
ATE526581T1 (de) 2007-01-08 2011-10-15 Univ City Hong Kong Verfahren zum screening eines agens mit angiogen- modulierenden aktivitäten unter verwendung eines teleost-embryos
US7897363B2 (en) 2007-06-12 2011-03-01 Phylonix Pharmaceuticals, Inc. Methods of screening an agent for an activity in an isolated eye of a teleost
EP2240604B1 (de) 2008-01-18 2012-07-25 North Carolina State University Peptide und verfahren zu ihrer verwendung als therapeutika und screeningmittel
JP5597200B2 (ja) * 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムｐ４５０３ａ酵素を検出するための方法
US8687857B2 (en) 2008-11-07 2014-04-01 General Electric Company Systems and methods for automated extraction of high-content information from whole organisms
US20100119119A1 (en) * 2008-11-07 2010-05-13 General Electric Company Automated systems and methods for screening zebrafish
EP2452192A1 (de) * 2009-07-08 2012-05-16 Zf Screens B.V. Hochdurchsatzverfahren und system für in-vivo-screening
US8865630B2 (en) * 2010-02-26 2014-10-21 Massachusetts Institute Of Technology High-throughput platform for in-vivo sub-cellular screens on vertebrate larvae
KR101800878B1 (ko) * 2010-03-31 2017-11-27 전남대학교 산학협력단 비-형광성 형광 단백질을 이용한 유전독성 분석방법
JP2014519816A (ja) 2011-05-06 2014-08-21 フィロニクス ファーマシューティカルズ，インコーポレイテッド 粒子を液体から取り出し、それを保持装置に入れるための方法および装置
EP3099683B1 (de) 2014-01-29 2020-08-05 Promega Corporation Chinonmaskierte sonden als markierungsreagenzien für zellaufnahmemessungen
US12478661B2 (en) 2017-10-03 2025-11-25 The Johns Hopkins University Lung cell treatments to prevent or treat disease
CN110865056A (zh) * 2019-11-06 2020-03-06 南通大学 一种转基因斑马鱼蛋白荧光的保存方法
CA3178684A1 (en) * 2020-03-31 2021-10-07 Sky Pharma Co., Ltd. Method for screening for, method for producing, and method for designing drug active ingredients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329424A (en) 1975-09-04 1982-05-11 Merck & Co., Inc. Macroscopic method for determining cytopathic effects in viral assay
JPS5399992A (en) 1977-02-10 1978-08-31 Hitachi Ltd Water quality fluctuation detector
ZA793568B (en) 1978-07-26 1981-02-25 Duphar Int Res Algicidal composition
GB2080948B (en) 1980-08-04 1983-09-21 Euratom Apparatus and method for measuring the toxicity of pollutants to aquatic living organisms
US4816392A (en) 1984-10-02 1989-03-28 Research Corporation Of The University Of Hawaii Rapid stick test for detection of ciguatoxin and other polyether toxins from tissues
US5510099A (en) 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
DE3801476A1 (de) 1988-01-20 1989-08-03 Henkel Kgaa Zusammensetzungen zur befreiung festgesetzter bohrgestaenge
US5190920A (en) 1990-09-24 1993-03-02 W. R. Grace & Co.-Conn. Method for using synthetic analogs of thrombospondin for inhibiting metastasis activity
US5326692B1 (en) 1992-05-13 1996-04-30 Molecular Probes Inc Fluorescent microparticles with controllable enhanced stokes shift
DE4113393C2 (de) * 1991-04-24 1993-10-14 Ulrich Dr Schiele Testverfahren für wundheilungs- und angiogenesefördernde Substanzen
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5424209A (en) 1993-03-19 1995-06-13 Kearney; George P. Automated cell culture and testing system
US5658751A (en) 1993-04-13 1997-08-19 Molecular Probes, Inc. Substituted unsymmetrical cyanine dyes with selected permeability
CA2161771C (en) 1993-04-30 2009-01-13 L. David Tomei Methods of identifying potentially therapeutically effective agents and cell strains for use therein
US5565187A (en) 1993-06-01 1996-10-15 Zikria; Bashir Methods for studying capillary circulation using fish fry and tadpoles
US5491084A (en) 1993-09-10 1996-02-13 The Trustees Of Columbia University In The City Of New York Uses of green-fluorescent protein
WO1995011989A1 (en) * 1993-10-29 1995-05-04 Invitro International In vitro fluid toxicity bioassay
DE4401868C1 (de) 1994-01-22 1995-02-16 Lobbe Xenex Gmbh Mikrobielles Verfahren zum Nachweis von Schadstoffen
WO1996003034A1 (en) 1994-07-27 1996-02-08 Massachusetts Institute Of Technology Method for retroviral vector insertion in fish
US5593678A (en) * 1994-10-11 1997-01-14 University Of Georgia Research Foundation Protection of teleost fish
FR2728790B1 (fr) 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5932418A (en) * 1996-04-08 1999-08-03 Naiad Systems, Inc. Fish embryo screening test for genotoxic agents using three different developmental life stages
GB9701245D0 (en) * 1997-01-22 1997-03-12 Eisai Co Ltd Method of screening compounds
US6380458B1 (en) 1997-06-09 2002-04-30 Medical College Of Georgia Research Institute, Inc. Cell-lineage specific expression in transgenic zebrafish
US7951989B2 (en) 1998-02-23 2011-05-31 Phylonix Pharmaceuticals, Inc. Methods of screening agents for activity using teleosts
EP1878799B1 (de) 1998-02-23 2011-06-08 Phylonix Pharmaceuticals, Inc. Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
US6656449B1 (en) 1998-02-23 2003-12-02 Phylonix Pharmaceuticals, Inc. Methods of screening agents for activity using teleosts
EP1290437A1 (de) 2000-05-27 2003-03-12 Exelixis Deutschland GmbH Verfahren zur identifizierung von agenzien und genen, die die kardiovaskuläre funktion beeinflussen
US6867349B2 (en) 2000-07-31 2005-03-15 Regents Of The University Of Minnesota Inhibition of gene expression using polynucleotide analogues
EP1463820A4 (de) 2001-12-17 2007-09-05 Childrens Medical Center Verfahren zum screening von verbindungen
WO2004047634A1 (en) 2002-11-20 2004-06-10 The General Hospital Corporation Zebrafish assay
GB0403490D0 (en) 2004-02-17 2004-03-24 Daniolabs Ltd Screening methods

Also Published As

Publication number Publication date
US20060104905A1 (en) 2006-05-18
US7435870B2 (en) 2008-10-14
US20020025297A1 (en) 2002-02-28
EP1548123A1 (de) 2005-06-29
EP1066402A1 (de) 2001-01-10
US7041276B2 (en) 2006-05-09
US6299858B1 (en) 2001-10-09
JP2002504667A (ja) 2002-02-12
EP1878799A3 (de) 2008-01-23
AU3307499A (en) 1999-09-06
JP4383533B2 (ja) 2009-12-16
EP1878799B1 (de) 2011-06-08
AU749688B2 (en) 2002-07-04
CA2320406A1 (en) 1999-08-26
ATE512233T1 (de) 2011-06-15
WO1999042606A1 (en) 1999-08-26
CA2320406C (en) 2011-06-21
JP2009186490A (ja) 2009-08-20
DE69925362T2 (de) 2006-01-19
EP1066402A4 (de) 2001-06-13
EP1878799A2 (de) 2008-01-16
DE69925362D1 (de) 2005-06-23
EP1066402B1 (de) 2005-05-18

Similar Documents

Publication Publication Date Title
ATE295899T1 (de) Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten
BG46598A3 (bg) Метод за получаване на алфа-хетероциклично заместени толунитрили
DE69737735D1 (de) Immortalisierte zelllinien für die wachstum von viren
DE69920006D1 (de) Verfahren und vorrichtung für elektrochemische messungen unter verwendung von statistischen methoden
DE69938867D1 (de) Verfahren und verwendung von anordungen von proteinfixierungsmitteln
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
TR200100754T2 (tr) Glausomanın tedavi edilmesi için serotonerjik 5HT2.
ATE536372T1 (de) Verfahren zur hoher expression der aktiven form von lymphotoxin-beta-rezeptor-immunglobulin fusionsproteinen, und deren reinigung
TR200001313T2 (tr) Protein etkileşimlerini ve fonksiyonel ilişkileri kaydeden tarama sistemleri
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69927424D1 (de) Netzwerkgerät (z.B. Repeater) und Testverfahren dafür
DE69937573D1 (de) Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen
DE69816516D1 (de) Laservorrichtung und Verfahren für Laseremission unter Verwendung desselben
EP0787207A4 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
DE60021960D1 (de) Verfahren zur Kompensation von Neigung und/oder Defokussierung, und Vorrichtung für dasselbige
ATE395433T1 (de) Screeningverfahren für geeignete wirkstoffe
WO2001070776A3 (en) Nimr compositions and their methods of use
DK1125500T3 (da) Værktøj, udstyr og fremgangsmåde til forskæring af mørbraden
DE69725459D1 (de) Substituierte 1,2,3,4-tetrahydro-2-dibenzofuranamine und 2-aminocyclohepta(b)benzofurane
FI980697A7 (fi) Menetelmä metallia sekä orgaanista ainesta sisältävän materiaalin käsittelemiseksi, johon sisältyy metallin erotus
DE69922378D1 (de) Oxidierte sulfurierte distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE69837612D1 (de) Mutiertes bioluminiszenz-protein und verfahren für seine herstellung.
ATE178309T1 (de) Verfahren zum unschädlichmachen von herbiziden im getreide unter verwendung von 5-aryloxy-1,2- (disubstituierten) benzolverbindungen
DE59509176D1 (de) Ledergerbstoffe und Stellmittel für Farbstoffe
DE69826029D1 (de) Acetyl-coa-carboxylase von candida albicans

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties